research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride
Finasteride may cause suicidal thoughts and mental side effects, especially in young people with hair loss.
research Assessing finasteride-associated sexual dysfunction using the FAERS database
Finasteride use linked to increased risk of sexual dysfunction, especially in younger people.
research Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia
Finasteride may cause side effects; more research needed.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
research Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.
research Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.
research Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System
Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
research A Global COVID-19 Pandemic Needs an Integrated Global Response
A global, inclusive approach is needed to address COVID-19 and protect vulnerable groups.
research Candidate genes of SARS-CoV-2 gender susceptibility
Men are more affected by COVID-19 due to differences in immune responses and protein expression.
research Additional Benefit Scoring During Health Technology Assessment in Germany - Its Drivers and Impact on Pricing and Discount for Orphan Drugs
Orphan drug benefit scores in Germany are influenced by phase III data and lack of alternatives, but not linked to price or discounts.
research Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
research Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases
Certain drugs can cause male infertility, so fertility counseling and sperm preservation are advised.
research Anais do V International Workshop on Rational Use of Medicines.
The workshop promoted better medicine use and health practices through global collaboration.
research Anais do V International Workshop on Rational Use of Medicines
The workshop successfully promoted better medicine use and international collaboration.
research Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
research FOXN1: A Master Regulator Gene of Thymic Epithelial Development Program
The FOXN1 gene is crucial for developing immune cells and preventing immune disorders.
research Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates
The document concludes that recognizing and treating cutaneous lupus erythematosus early is crucial for managing the skin and potential systemic symptoms.
research Older women’s negative psychological and physical experiences with injectable cosmetic treatments to the face
Older women reported negative physical and psychological effects from Botox and facial fillers, feeling neglected by the medical system.
research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
research Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
research The Role of Janus Kinase Inhibitors in Dermatology
Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
research Semaglutide and the Skin: An Overview of Current Evidence
Semaglutide may help some skin disorders but can also cause skin issues.
research Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
GLP-1 receptor agonists may cause hair loss, but more research is needed.
research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.
research Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
research Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.